We are live on
!
Find out more
VCG
Vantage Consulting Group Portfolio holdings
AUM
$19.7M
1-Year Est. Return
280.87%
This Fund
S&P 500
This Quarter
Est. Return
+17.65%
1 Year Est. Return
+280.87%
3 Year Est. Return
+261.08%
5 Year Est. Return
+180.34%
10 Year Est. Return
–
AUM
$1.23B
AUM Growth
–
Cap. Flow
+$1.06B
Cap. Flow
% of AUM
86.51%
Top 10 Holdings %
Top 10 Hldgs %
94.5%
Holding
1,884
New
1,883
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$911M |
| 2 |
ADC Therapeutics
ADCT
|
+$55.1M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$25.5M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$5.96M |
| 5 |
Kroger
KR
|
+$366K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.04% |
| 2 | Technology | 0.89% |
| 3 | Consumer Discretionary | 0.79% |
| 4 | Industrials | 0.61% |
| 5 | Consumer Staples | 0.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
3M
MMM
$93.6B
| $69K | 0.01% |
+475
| New | +$67.4K |
|
327
Tyler Technologies
TYL
$12.8B
| $69K | 0.01% |
+157
| New | +$64.8K |
|
328
Western Union
WU
$2.28B
| $69K | 0.01% |
+3,154
| New | +$68.4K |
|
329
Equity Residential
EQR
$25.4B
| $68K | 0.01% |
+1,148
| New | +$64.9K |
|
330
MGP Ingredients
MGPI
$366M
| $68K | 0.01% |
+1,445
| New | +$62.2K |
|
331
RTX Corp
RTX
$294B
| $68K | 0.01% |
+953
| New | +$62.6K |
|
332
UDR
UDR
$12.4B
| $68K | 0.01% |
+1,776
| New | +$64.8K |
|
|
ZYXI
333
DELISTED
Zynex
ZYXI
| $68K | 0.01% |
+5,575
| New | +$72.5K |
|
|
AVTA
334
DELISTED
Avantax, Inc. Common Stock
AVTA
| $68K | 0.01% |
+4,289
| New | +$52.3K |
|
|
DSPG
335
DELISTED
DSP Group Inc
DSPG
| $68K | 0.01% |
+4,089
| New | +$62.9K |
|
336
American Airlines Group
AAL
$11B
| $67K | 0.01% |
+4,232
| New | +$58.6K |
|
337
AvalonBay Communities
AVB
$27B
| $67K | 0.01% |
+417
| New | +$66.3K |
|
338
Cytokinetics
CYTK
$10.7B
| $67K | 0.01% |
+3,248
| New | +$59.4K |
|
339
GE Aerospace
GE
$391B
| $67K | 0.01% |
+1,246
| New | +$55.8K |
|
340
Xencor
XNCR
$1.48B
| $67K | 0.01% |
+1,525
| New | +$63.1K |
|
|
CHCT
341
Community Healthcare Trust
CHCT
$506M
| $66K | 0.01% |
+1,401
| New | +$66.6K |
|
342
CareTrust REIT
CTRE
$9.65B
| $66K | 0.01% |
+2,990
| New | +$58.9K |
|
343
Essex Property Trust
ESS
$18.5B
| $66K | 0.01% |
+277
| New | +$63.9K |
|
344
Stewart Information Services
STC
$2.09B
| $66K | 0.01% |
+1,368
| New | +$62.4K |
|
|
LL
345
DELISTED
LL Flooring Holdings, Inc.
LL
| $66K | 0.01% |
+2,157
| New | +$60K |
|
|
LCI
346
DELISTED
Lannett Company, Inc.
LCI
| $66K | 0.01% |
+2,527
| New | +$66K |
|
347
Coherus Oncology
CHRS
$228M
| $65K | 0.01% |
+3,712
| New | +$66.1K |
|
348
Cooper Companies
COO
$14.6B
| $65K | 0.01% |
+712
| New | +$61.1K |
|
|
DHC
349
Diversified Healthcare Trust
DHC
$2.13B
| $65K | 0.01% |
+15,753
| New | +$62.1K |
|
350
Edwards Lifesciences
EW
$51.6B
| $65K | 0.01% |
+710
| New | +$58.9K |
|
Similar funds
MVG
NCM
FFGIM
PIM
HFG
SWM
ICM
SM
Vantage Consulting Group's Q4 2020 Portfolio in Review
Q4 2020 is the first quarter with a 13F filing on record for Vantage Consulting Group, which disclosed 1,884 positions worth $1.23B. Its ten largest holdings account for 94% of the portfolio.
Its largest position is Royalty Pharma: 21,477,282 shares worth $1.07B.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, followed by Technology and Consumer Discretionary.
- Vantage Consulting Group's largest Q4 2020 buy was Royalty Pharma: 21,477,282 shares worth $1.07B.
- Vantage Consulting Group's ten largest holdings make up 94% of its $1.23B portfolio in Q4 2020.
- Vantage Consulting Group disclosed 1,884 positions in Q4 2020, its first 13F filing on record.
Based on Vantage Consulting Group's 13F filing for Q4 2020, filed 12 Feb 2021.